对一种罕见疾病的新疗法:为患有巨细胞激活综合征的患者提供连续阿纳金拉输液
Mitch Gullickson1, Laura Nichols2,1, Meghan Scheibe3
1Internal Medicine, Sanford Health, Fargo, USA.
Cureus
|September 5, 2023
概括
巨细胞激活综合征 (MAS) 是一种严重的免疫过度反应,在患有成人开始的斯蒂尔病的患者中,可以由细胞巨病毒 (CMV) 等感染引发. 在这种情况下,阿纳金拉和甘西克洛维尔有效地治疗了MAS,为传统疗法提供了毒性较低的替代方案.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 传染性疾病 传染性疾病
背景情况:
- 大细胞激活综合征 (MAS) 是由免疫系统过度刺激引起的危及生命的血细胞淋巴细胞细胞瘤 (HLH) 形式.
- 成人发病的斯蒂尔病 (AOSD) 是一种炎症状况,可以导致MAS,出现发烧,皮疹和关节炎.
- 散布型细胞巨乳病毒 (CMV) 感染是潜在的引发MAS在患有潜在的类风湿病的患者.
研究的目的:
- 在可能患有AOSD的患者中报告传播CMV感染后的MAS病例.
- 要突出在这个临床场景中满足MAS的诊断标准.
- 讨论对anakinra和ganciclovir的治疗反应.
主要方法:
- 案例报告的呈现方式.
- 诊断评估包括骨髓活检以检测血细胞瘤.
- 临床监测患者对治疗的反应.
主要成果:
- 患者呈现出发烧,细胞衰减,费里水平升高,血细胞分裂,纤维素低,大,符合MAS标准.
- 通过连续输注阿纳金拉和甘西克洛维尔,获得了成功的治疗.
- 患者对这种治疗方案表现出积极的反应.
结论:
- 在患有AOSD的患者中,MAS可能是传播的CMV感染的次要原因.
- 与传统药物相比,像阿纳金拉这样的干白素-1 抑制剂代表了对MAS的有希望的,较少的细胞毒性治疗选择.
- 与阿纳金拉和甘西克洛维尔的联合治疗可以有效地管理由CMV感染引发的MAS.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173
01:29Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152